Skip to main content
PharmAbcine Inc. logo

PharmAbcine Inc. — Investor Relations & Filings

Ticker · 208340 ISIN · KR7208340000 KO Manufacturing
Open in API
Filings indexed 461 across all filing types
Latest filing 2024-07-25 Director's Dealing
Country KR South Korea
Listing KO 208340

About PharmAbcine Inc.

http://pharmabcine.com/

PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (often referred to as a 'Section 16' equivalent filing) where company insiders report their shareholdings and changes in ownership. This falls under the category of Director's Dealing (DIRS).
2024-07-25 Korean
기타시장안내 (코스닥시장위원회 심의·의결결과 등 안내)
Delisting Announcement Classification · 100% confidence The document is a short regulatory announcement from the KOSDAQ market committee regarding the delisting decision for PharmAbcine. It explicitly discusses the deliberation and resolution of delisting, which fits the definition of a delisting announcement.
2024-07-24 Korean
주권매매거래정지기간변경 (상장폐지 사유 발생)
Delisting Announcement Classification · 100% confidence The document is a short regulatory notice regarding the suspension of stock trading for (주)파멥신 due to delisting-related events. It cites specific KOSDAQ market regulations and provides details on the duration of the trading suspension. Since it is a regulatory announcement regarding the status of the company's listing and trading, it falls under the RNS category.
2024-07-24 Korean
증권발행결과(자율공시) (제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from a Korean company (PharmAbcine) detailing the results of a third-party capital increase (share issuance). It specifies the number of shares issued, the amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2024-07-23 Korean
최대주주변경
Major Shareholding Notification Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding a change in the company's largest shareholder (최대주주변경). It details the before-and-after shareholding structure, the reason for the change (third-party capital increase), and information about the new controlling shareholder. This falls under the category of regulatory filings related to corporate structure and ownership changes, which is best classified as RNS (Regulatory Filings) as it is a standard disclosure of a material corporate event.
2024-07-23 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used to solicit shareholder votes for an upcoming Extraordinary General Meeting. It contains details about the meeting agenda, director candidates, and proposed changes to the articles of incorporation. This falls under the 'Proxy Solicitation & Information Statement' category.
2024-07-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.